The GLOW Pregnancy Registry

Are you pregnant and diagnosed with plaque psoriasis, psoriatic arthritis, or Crohn's disease?

Have you used SKYRIZI® (risankizumab-rzaa) or other medications for these conditions during your pregnancy or just prior to becoming pregnant?

Plaque psoriasis, psoriatic arthritis, and Crohn's disease are complex and chronic conditions that can be debilitating. Help future pregnant women, doctors, and researchers understand the safety of medications that can provide some relief.

Are you a healthcare provider who treats pregnant women with plaque psoriasis, psoriatic arthritis, or Crohn's disease?

Help us learn more about the safety of using SKYRIZI® (risankizumab-rzaa) and other medications for these conditions during pregnancy.

This website is supported by AbbVie Clinical Development Operations.

The GLOW Pregnancy Registry

Many pregnant women knowingly take medications during pregnancy, or before they know they are pregnant. Since pregnant women are excluded from most research studies, little is known about the safety of medication use during pregnancy. Pregnancy registries collect health information on pregnant women and their newborn babies. This information can then be used to help doctors and patients make informed decisions about medication use during pregnancy.

The goal of the GLOW Pregnancy Registry is to help doctors, patients, and researchers better understand the safety of SKYRIZI® (risankizumab-rzaa) and other similar medications when used during pregnancy. Pregnant women in the United States with plaque psoriasis, psoriatic arthritis, or Crohn's disease may be eligible to participate. The study collects health information from enrolled pregnant women and their healthcare providers related to their pregnancies and developing babies up to 1 year of age.

Would you like to participate?

Enroll in the Registry

What is SKYRIZI® (risankizumab-rzaa)?

SKYRIZI® (risankizumab-rzaa) is a prescription medicine used to treat adults with:

  • Moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
  • Active psoriatic arthritis (PsA)
  • Moderate to severe Crohn's disease

IMPORTANT SAFETY CONSIDERATIONS

SKYRIZI® (risankizumab-rzaa) may cause serious side effects, including:

  • Serious allergic reactions: Stop using SKYRIZI® and get emergency medical help right away if you get any symptoms of a serious allergic reaction.
  • Infections: SKYRIZI® may increase your risk of infections. Before starting treatment, your doctor should check you for infections and tuberculosis. Tell your doctor right away if you have an infection or symptoms of one.

Do not use SKYRIZI® if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI®.

  • Also, tell your doctor if you plan to or recently received a vaccine.
  • Liver problems in Crohn’s disease: A person with Crohn’s disease who received SKYRIZI® through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your doctor will do liver blood tests before and during treatment and may stop treatment with SKYRIZI® if you develop liver problems.
  • The most common side effects of SKYRIZI® in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
  • The most common side effects of SKYRIZI® in people treated for Crohn’s disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection.

These are not all the possible side effects of SKYRIZI®. Call your doctor for medical advice about side effects.

Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI® (risankizumab-rzaa).

Learn more about the Registry

I am a Patient I am a Healthcare Provider

GLOW Pregnancy Registry toll-free number 1-877-302-2161